Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan
Because of the increasing use of pegcetacoplan in routine clinical practice, it is important that both clinicians and laboratory specialists are aware of these unexpected therapy-induced laboratory findings.
Authors
- Marloes A. H. M. Michels
- Corrie de Kat Angelino
- Evelien G. G. Sprenkeler (ORCID: https://orcid.org/0000-0002-4961-0155)
- Joannes F.M. Jacobs (ORCID: https://orcid.org/0000-0002-6208-6386)
- Nicole C. A. J. van de Kar (ORCID: https://orcid.org/0000-0002-1990-1189)
- Mendy ter Avest (ORCID: https://orcid.org/0000-0001-5757-4919)
- Renate van der Molen
- Jeroen D. Langereis (ORCID: https://orcid.org/0000-0001-5317-3202)
- Caroline Duineveld
- Saskia Langemeijer (ORCID: https://orcid.org/0000-0002-0366-0800)
- Jolein Gloerich (ORCID: https://orcid.org/0000-0001-5976-8426)
- Anne-Els van de Logt
- Amber van Deelen
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1515/cclm-2025-1270
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00